Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FEV1 is a major prognostic factor in diverse heart failure populations: findings from the Global Heart Failure registry.

ESC heart failure·2026
Same author

The European BestAgeing Study on microRNA candidates reveals distinct signatures with diagnostic and prognostic potential in cardiovascular disease.

BMC medicine·2025
Same author

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.

The New England journal of medicine·2025
Same author

The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus.

Global heart·2025
Same author

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.

Nature medicine·2024
Same author

Empagliflozin after Acute Myocardial Infarction.

The New England journal of medicine·2024

Related Experiment Video

Updated: May 9, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

Renal effects of levosimendan: a consensus report.

Mehmet B Yilmaz1, Elena Grossini, José C Silva Cardoso

  • 1Department of Cardiology, Cumhuriyet University School of Medicine, Sivas, Turkey, cardioceptor@gmail.com.

Cardiovascular Drugs and Therapy
|August 10, 2013
PubMed
Summary

Levosimendan may improve renal function in patients with compromised cardiac function, though evidence varies. Further randomized trials are needed to confirm its renal benefits and understand its mechanisms.

Related Experiment Videos

Last Updated: May 9, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Renal dysfunction frequently complicates conditions with compromised cardiac function, such as heart failure, cardiac surgery, and sepsis, leading to increased morbidity and mortality.
  • Levosimendan, a calcium sensitizer and potassium channel opener, is utilized in treating acute heart failure.

Purpose of the Study:

  • To review and synthesize the current understanding of levosimendan's effects on renal function.
  • To establish a consensus among experts regarding the interpretation of existing research on levosimendan and renal outcomes.

Main Methods:

  • A consensus panel of 25 scientists and clinicians from 15 European countries reviewed non-clinical and clinical data on levosimendan's renal effects.
  • Data synthesis included interpretation of findings from randomized controlled trials and uncontrolled studies.

Main Results:

  • Most reports suggest levosimendan improves renal function in heart failure, sepsis, and post-cardiac surgery settings.
  • However, study design heterogeneity necessitates caution; the largest heart failure study (REVIVE I and II) showed no significant renal changes.
  • The mechanism may involve levosimendan's opening of mitochondrial KATP channels, inducing a preconditioning effect.

Conclusions:

  • There is a strong rationale for conducting randomized controlled trials to definitively assess levosimendan's beneficial effects on renal function.
  • Ongoing research, such as the LeoPARDS trial, aims to evaluate levosimendan's role in preventing acute organ dysfunction in sepsis.